X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ASTRAZENECA PHARMA VENUS REMEDIES/
ASTRAZENECA PHARMA
 
P/E (TTM) x -3.5 391.7 - View Chart
P/BV x 0.1 19.2 0.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ASTRAZENECA PHARMA
Mar-14
VENUS REMEDIES/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1261,285 9.8%   
Low Rs61634 9.6%   
Sales per share (Unadj.) Rs301.8189.6 159.2%  
Earnings per share (Unadj.) Rs-24.9-0.2 12,215.3%  
Cash flow per share (Unadj.) Rs2.53.8 66.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.368.6 427.3%  
Shares outstanding (eoy) m12.3425.00 49.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.35.1 6.1%   
Avg P/E ratio x-3.8-4,712.7 0.1%  
P/CF ratio (eoy) x36.7249.6 14.7%  
Price / Book Value ratio x0.314.0 2.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,15423,988 4.8%   
No. of employees `0000.91.6 59.3%   
Total wages/salary Rs m3931,605 24.5%   
Avg. sales/employee Rs Th4,026.13,040.2 132.4%   
Avg. wages/employee Rs Th425.01,029.2 41.3%   
Avg. net profit/employee Rs Th-331.8-3.3 10,162.1%   
INCOME DATA
Net Sales Rs m3,7244,740 78.6%  
Other income Rs m2392 24.4%   
Total revenues Rs m3,7474,832 77.5%   
Gross profit Rs m395-130 -304.2%  
Depreciation Rs m338101 334.3%   
Interest Rs m3540-   
Profit before tax Rs m-275-139 198.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m325 620.8%   
Profit after tax Rs m-307-5 6,029.5%  
Gross profit margin %10.6-2.7 -387.1%  
Effective tax rate %-11.5-3.7 313.2%   
Net profit margin %-8.2-0.1 7,673.8%  
BALANCE SHEET DATA
Current assets Rs m2,6382,726 96.7%   
Current liabilities Rs m2,3052,435 94.6%   
Net working cap to sales %8.96.1 145.5%  
Current ratio x1.11.1 102.2%  
Inventory Days Days13574 183.6%  
Debtors Days Days4641 113.7%  
Net fixed assets Rs m4,8711,035 470.5%   
Share capital Rs m12350 246.8%   
"Free" reserves Rs m3,496942 370.9%   
Net worth Rs m3,6191,716 210.9%   
Long term debt Rs m1,3740-   
Total assets Rs m7,5094,156 180.7%  
Interest coverage x0.2NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.51.1 43.5%   
Return on assets %0.6-0.1 -515.4%  
Return on equity %-8.5-0.3 2,858.9%  
Return on capital %1.60-  
Exports to sales %05.7 0.0%   
Imports to sales %13.96.5 214.6%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs m517306 168.6%   
Fx inflow Rs m0375 0.0%   
Fx outflow Rs m517470 109.9%   
Net fx Rs m-517-96 540.6%   
CASH FLOW
From Operations Rs m514-8 -6,350.6%  
From Investments Rs m-123-146 84.5%  
From Financial Activity Rs m-387862 -44.9%  
Net Cashflow Rs m4709 0.6%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.2 0.3 60.0%  
FIIs % 0.6 15.7 3.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 9.1 729.7%  
Shareholders   20,121 12,856 156.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks ahead of Election Results; Realty Stocks Plummet(Closing)

Indian share markets settled around 2% lower today following a sell-off in the global markets and due to uncertainty over the outcome of state assembly elections tomorrow.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Dec 10, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS